- Motley Fool•15 hours ago
Looking for stocks with huge upside potential? These might be worth a closer look.
- Investopedia•7 days ago
Though the drug failed in phase 2 study, Ultragenyx has announced it plans to proceed with phase 3 studies.
- Investopedia•22 days ago
Supernus will see generic competition for its key epilepsy drug Trokendi XR in 2023, much earlier than its patent expiry in 2027.
SUPN : Summary for Supernus Pharmaceuticals, Inc. - Yahoo Finance
Supernus Pharmaceuticals, Inc. (SUPN)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||30.05 x 100|
|Ask||65.00 x 200|
|Day's Range||30.70 - 31.43|
|52 Week Range||14.14 - 31.43|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||17.51|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|